- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05871788
Biomarkers in Patients With Metastatic Breast Cancer (BIOPEACE)
In order to allow Tunisian patients with breast cancer to access immunotherapies, and innovative treatments to extend life expectancy of patients with breast cancer with a poor prognosis, it is important to study the epidemiological profile of Tunisian cancers breast, in terms of PD-L1 expression, tumor mutational burden (TMB), microsatellite instability status (MSI) and rate of TILs, in metastatic and locally advanced cases, in Tunis, over a one-year follow-up period.
It is also important to study other inflammatory and tumor biomarkers which would have a prognostic or even therapeutic value:
- serum dosage of LDH (lactate dehydrogenase)
- IL-6 (interleukin 6)
- CRP (C-reactive protein)
- absolute count of lymphocytes (CLA) and eosinophils
- quantification of circulating tumor DNA before treatment and under treatment. The primary objective id to identify the epidemiological profile of the biological signature (PD-L1 / TMB / MSI/HRD/ TILs) of patients with locally advanced or metastatic breast carcinoma before and during the systemic treatment.
Study Overview
Status
Intervention / Treatment
Detailed Description
Procedure:
- Verification of the inclusion / non-inclusion criteria
- Signing the consent form
- Surgical, Medical and family history, ongoing treatments
- Clinical Examination1
- Radiological examinations 2
- TNM Classification (Appendix 3)
- Standard biochemical assessment 3
- Inflammatory assessment (CRP, LDH, IL6)
- Hematological assessment (NFS, platelets)
- Tumor markers (ACE, CA15-3)
Histological and molecular examination 4:
- Expression PD-L1 by IHC (Immuno-Histochemistry)
- TILs by IHC
- - MSI status: MMR * proteins (Mismatch Repair Protein) (Appendix 4) by NGS via TruSight™ Oncology 500 Kit (Illumina) , if PD-L1>1%
- Score HRD : by NGS via TruSight™ Oncology 500 Kit (Illumina) , if PD-L1>1%
- TMB mutational burden by next generation sequencing "Next Generation Sequencing" (NGS) via TruSight™ Oncology 500 Kit (Illumina) if PD-L1>1%
- tDNA by digital PCR
- Radiological evaluation5
- Indication of surgery? (if yes type of surgery to be specified)
- Evaluation of adverse events / effects: Tolerance of the previous treatment
Completion the source documents and the eCRF
Clinical Exam1:
- General State according to the WHO classification or according to the Karnowsky Index
- Breast examination: inspection (symmetry, appearance of the skin), palpation (size of the tumor, presence of mammary discharge).
- Examination of the axillary and supraclavicular lymph node areas
- Abdominal examination
- Pulmonary auscultation
- Skeleton examination Radiological examination2:
- Mammography and echo-mammary
- Thoraco-abdomino-pelvic CT scan
- Bone scintigraphy
- Cardiac ultrasound
Standard biochemical balance3:
Blood group, creatininemia, blood ionogram, calcemia, glycemia, bilirubin, transaminases, gamma-GT, alkaline phosphatases, total cholesterol, triglycerides, uric acid, albuminemia.
Histological examination4:
- Biopsy with part number assigned by the laboratory, name of the laboratory
- Histological type
- Grade of Scarff-Bloom and Richardson (SBR)
- Estrogen receptors, progesterone receptors
- Her2Neu
- Ki67
- PD-L1
- TILs
- MMR
Molecular Examination4:
- MSI status by pentaplex PCR and capillary electrophoresis by NGS platform via the TruSight™ kit Oncology 500 (Illumina)
- HRD Score by NGS platform via the TruSight™ kit Oncology 500 (Illumina)
- Mutational burden TMB by NGS platform via the TruSight™ kit Oncology 500 (Illumina)
- Circulating tumor DNA by digital PCR Radiological assessment5:
- If the stage is locally advanced (appendix 3): Breast ultrasound +/- Mammography +/- Breast MRI
If metastatic stage: Thoraco-abdomino-pelvic CT scan 12 | 27 Visit details
• Initial visit D0 (V1)
- Signature of informed consent form
- Verification of inclusion / non-inclusion criteria
- Medical, surgical and family history
- Current treatments
- Clinical examination1
- Radiological examinations2
- TNM classification
- Standard biochemical assessment3
- Inflammatory assessment (CRP, LDH, IL6)
- Hematological assessment (NFS, platelets)
- Tumor markers (ACE, CA15-3)
- Histological examination with immunohistochemistry and molecular4:
- Biopsy with part number assigned by the lab, name of the lab
- Histological type
- SBR grade
- Estrogen receptors, progesterone receptors
- Her2Neu
- Ki67
- PD-L1
- TILs
- MMR
- MSI
- HRD
- TMB mutational charge
ctDNA o Completion of source documents and eCRF
Visit after 3 chemotherapy treatment cycles (V2)
- Current treatments
- Clinical examination1
- Hematological assessment (NFS, platelets)
- Tumor markers (ACE, CA15-3)
- Radiological assessment5
- Evaluation of adverse events / effects: Tolerance of the previous treatment
- Completion of source documents and eCRF
Assessment visit (V3) o Current treatments
o Clinical examination1
- TNM classification
- Inflammatory assessment (CRP, LDH, IL6)
- Hematological assessment (NFS, platelets)
- Tumor markers (ACE, CA15-3)
- Histological examination with immunohistochemistry and molecular4:
- Biopsy with part number assigned by the lab, name of the lab
- Histological type
- SBR grade 13 | 27
- Estrogen receptors, progesterone receptors
- Her2Neu
- Ki67
- PD-L1
- TILs
ctDNA
o Radiological assessment5
o Assessment of adverse events / effects
o Fill in the source files and the eCRF
Follow-up visit at 3 months (V4)
o Current treatments
o Clinical examination1
o Tumor markers (ACE, CA15-3)
o Radiological examinations2
o Evaluation of adverse events / effects
- Completion of source documents and eCRF
Follow-up visit at 6 months (V5) o Current treatments o Clinical examination1 o Tumor markers (ACE, CA15-3)
- Radiological examinations2
- Evaluation of adverse events / effects
- Completion of source documents and eCRF
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Monia Malek, MD
- Phone Number: 00216 28 101 505
- Email: monia.malek@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years old.
- Signed informed consent
- Histological evidence of breast carcinoma.
- Locally advanced (stage III inoperable) or metastatic (stage IV) carcinoma, the metastases of which have been diagnosed straight away or after adjuvant or neoadjuvant treatment.
- No treatment for metastatic disease.
- Metastatic disease: histological evidence of metastasis
- Patients who will receive systemic treatment (chemotherapy, targeted therapy, hormone therapy)
- Life expectancy greater than 3 months
Exclusion Criteria:
- Non-epithelial breast cancer
- Non-biopsiable metastases
- Patients who have received before systemic treatment for metastatic disease (chemotherapy, targeted therapy, hormone therapy)
Patients with a contraindication to chemotherapy, and / or hormone therapy, and
/ or targeted therapy.
- Foreign patients
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of eligible patients for immunotherapy
Time Frame: 2023 to 2027
|
Identify the number of eligible patients for immunotherapy according to the epidemiological and biological profile
|
2023 to 2027
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relevance of immunotherapy in Tunisia
Time Frame: 2023 to 2027
|
Assess the relevance of the introduction of immunotherapy in Tunisia, by calculating the extension of the life expectancy (without disease and overall) of the patients who could benefit from this treatment, compared to the cost. - Identify the sub-population of patients who benefit most from immunotherapy in Tunisia |
2023 to 2027
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ECOCS2020-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Identify the Number of Eligible Patients for Immunotherapy According to the Epidemiological and Biological Profile in Tunisia
-
Tel-Aviv Sourasky Medical CenterCompletedConsecutive Subjects Who Are Suitable for a Coronary | Angioplasty of de Novo Lesion(s) in Native Coronary | Arteries Should be Screened for Eligibility. | A Total Number of 200 Patients Fulfilling the Selection | Criteria and Willing to Sign the Informed Consent Should | be Enrolled in the...Israel
-
Institut fuer FrauengesundheitNovartis; ClinSolUnknownis to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.Germany
-
Nan ShenNovartisNot yet recruitingCharacterize the Molecular Profile of Lupus Nephritis(LN) Patients to Understand Themechanism(s)Contributing to Patient Responsiveness to Soc | Integrated Analysis of LN Patient Molecular Profiling and Clinical Annotations to Understand LNdisease Heterogeneity for Disease Endotype | Validate the Association of the Candidate Biomarker Panel Proposed in Table 3-1 With LN Diseasemonitoring
-
Ziqiang LiActive, not recruitingComplete and Accurate Statistical Data of 60 Patients | CYP3A5*3 Genotypes of 60 Donors and Recipients Were Analyzed Accurately | Postoperative Tacrolimus Concentrations Were Accurately Recorded in 60 Patients | According to the Diagnosis and Grading Criteria of Acute Kidney Injury, the... and other conditionsChina
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingDescribe Typical Gray Scale/Color Doppler Ultrasound Features of Gestational Trophoblastic Neoplasia at the US Examination | To Assess if There Are Differences at the Baseline US Scan Between Low-risk and High-risk Patients | To Identify Ultrasound Predictors of Resistance to First-line... and other conditionsItaly
-
King Saud UniversityCompletedCollection of Clinical Data That Will be Used in This Study and Will Form a Data Bank for Asthma in Saudi Arabia | Identify Known and NOVEL Genetic Risk Factors Contributing to Asthma Susceptibility | Study the Mechanistic Roles of the Genetic Variants Within Major Asthma Susceptibility...Saudi Arabia
Clinical Trials on identify biomarkers
-
International Agency for Research on CancerFederico II University; Imperial College London; Fondazione IRCCS Istituto Nazionale... and other collaboratorsCompleted
-
Assistance Publique Hopitaux De MarseilleCompletedAmyloid Neuropathies | Transthyretin AmyloidosisFrance
-
Children's Hospital Medical Center, CincinnatiThe Leona M. and Harry B. Helmsley Charitable TrustActive, not recruiting
-
West China HospitalRecruitingBiomarkers | NeonateChina
-
Central Hospital, Nancy, FranceRecruiting
-
Istituto Clinico HumanitasIstituto Superiore di Sanità; Ospedale San Raffaele; University of Paris 5 -... and other collaboratorsUnknown
-
First Affiliated Hospital of Chongqing Medical...Unknown
-
Corporacion Parc TauliHospital Clinic of Barcelona; Germans Trias i Pujol Hospital; Hospital Arnau... and other collaboratorsUnknownPulmonary Disease, Chronic Obstructive | Exacerbation COPDSpain
-
Corporacion Parc TauliInstituto de Salud Carlos III; Consorcio Centro de Investigación Biomédica...Unknown
-
Far Eastern Memorial HospitalWithdrawnLower Urinary Tract SymptomsTaiwan